Avalon Health Economics LLC – Proving the economic value of your innovation

February 12, 2024

Reasonable and Fair Market Value of Medical Expenses

December 7, 2023

Can the Total be Greater than the Sum of the Parts? Assessing Damages in Product Liability

December 6, 2023

Product Liability and "Socially Optimal" Outcomes: The Importance of the Analyzing Cost-Benefit Tradeoffs in Healthcare Products and Services

December 5, 2023

Attributable Risk and Attributable Fraction: Litigation Applications

December 5, 2023

What are "Hedonic Damages," and Should They Matter in Litigation?

December 4, 2023

What Do Economists have to Say About Liability?

December 4, 2023

The Rise of Litigation Funding and Medical Funding in Personal Injury and Product Liability Lawsuits

January 4, 2022

Analysis of Dental and Vision Plan Non-Covered Services and Materials Mandates and the Projected Role of the DOC Access Act in the Vision and Dental Markets: An Update

June 15, 2021

Economic Evaluation and Market Access for Medical Devices in the U.S.: Implications of a U.S. Health Technology Assessment Agency

June 8, 2021

Count the Cost of Disability Caused by COVID-19

July 1, 2020

Online Simulation Model to Estimate the Total Costs of Tobacco Product Waste in Large U.S. Cities

June 18, 2020

Telehealth and Telemedicine in the Post-Pandemic Era

May 15, 2020

Moving Beyond 'Lives-Saved' From COVID-19

May 11, 2020

Economic Cycles and Product Development in Life Sciences

May 5, 2020

Avalon’s Andrew Briggs Conducted Work on the Excess Mortality Attributable to COVID-19 Featured in the Wall Street Journal

April 29, 2020

Cost Impact Model of a Novel Multi-mRNA Host Response Assay for Diagnosis and Risk Assessment of Acute Respiratory Tract Infections and Sepsis in the Emergency Department

April 27, 2020

Electronic Medical Records: Potential Issues in Litigation and Biomedical Research

April 17, 2020

Estimating QALY Losses Associated With Deaths in Hospital (COVID-19)

April 17, 2020

Applications of HEOR Analytics: Covariate-Adjusted Analysis of Phase 3 Clinical Trial Data of Lenvatinib versus Sorafenib in Hepatocellular Carcinoma

April 14, 2020

COVID-19: Update on Epidemiology & Costs

April 8, 2020

Distinguishing Between Viral and Bacterial Respiratory Infections

March 13, 2020

The Coronavirus: How Bad is it, Really?

February 10, 2020

What is the Reasonable Value of Future Medical Care?

December 23, 2019

How Important is ICER Preparation and Review for U.S. Market Access?

October 16, 2019

Avalon Health Economics Will Be At ISPOR Copenhagen 2019

September 16, 2019

New HEOR Publication: Monitoring Technology for Seniors

August 27, 2019

Avalon & Oberender Enter a New Collaboration

July 17, 2019

Using Payer Research to Assess Medical Device Market Access

June 20, 2019

Optometry’s Essential and Expanding Role in Health Care: Assured Quality and Greater Access for Healthier Communities

June 19, 2019

Healthcare Use Cases for Blockchain Technology

June 10, 2019

Smoke, Mirrors, and Wild Geese: What Should Be the Future Directions of HEOR in the 2020s?

March 14, 2019

Avalon Health Economics will be at ISPOR New Orleans, May 18 through May 22, 2019

December 26, 2018

Avalon Health Economics Collaborates with Acaster-LLoyd Consulting, Ltd.

September 28, 2018

Avalon Health Economics will be at ISPOR Barcelona, Nov. 10 through Nov. 14

December 1, 2017

Avalon CEO John Schneider will be speaking at the 4th Annual Conference on Health Outcomes, Data Communications, Market Access and Value-Based Contracting in Philadelphia, January 22-24, 2018.

October 1, 2017

Avalon CEO John Schneider will be presenting on the panel of "Blockchain Use-Cases, Brainstorm: Replacing the Middleman: Healthcare, Retail, Finance and More" at the Blockchain Economic Forum 2017 in NYC on October 31st.

October 1, 2017

Avalon Health Economics at the 20th Annual European Conference of ISPOR

April 1, 2017

AHE Presents: Symposium on Emerging Trends in U.S. Health Economic Evaluation: A Closer Look at the Role of Cost Effectiveness in U.S. Market Access, Tuesday May 9th in Morristown, NJ

February 22, 2017

The Value of Biopharmaceutical Innovation in the U.S.

December 7, 2016

The Evolving Landscape of U.S. Payer Coverage Decisions: The Role of Health Economics and Outcomes Research

Health Economics, Economic Research, Consulting, & Expert Services

We are a team of academic and industry health economics and outcomes researchers providing high quality, high value real world health economics analyses and modelling and health-related litigation support and expert testimony.

Services

Markets

Issue Briefs

Contact Us